Compare ALCO & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ALCO | CBIO |
|---|---|---|
| Founded | 1960 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.7M | 252.6M |
| IPO Year | N/A | N/A |
| Metric | ALCO | CBIO |
|---|---|---|
| Price | $36.52 | $13.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $25.60 |
| AVG Volume (30 Days) | 26.5K | ★ 186.2K |
| Earning Date | 11-24-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.55% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $44,066,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $24.76 | $9.81 |
| 52 Week High | $37.50 | $21.40 |
| Indicator | ALCO | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 61.04 | 56.08 |
| Support Level | $31.42 | $12.27 |
| Resistance Level | $37.50 | $16.35 |
| Average True Range (ATR) | 0.91 | 1.09 |
| MACD | 0.40 | -0.07 |
| Stochastic Oscillator | 77.35 | 38.72 |
Alico Inc is a Florida-based agribusiness and land management company that primarily focuses on citrus production and grove conservation. The company operates through two primary business units: Alico Citrus and Land Management and Other Operations. The Alico Citrus segment engages in the cultivation of citrus trees and delivers citrus to the processed and fresh citrus markets. It mainly serves the processed market and sells primarily Hamlin oranges and the Valencia variety to the orange juice processors. The Land Management and Other Operations segment engages in land leasing for recreational, conservation, and mining activities. Alico Citrus delivers most of the revenue as the firm's primary operating business unit.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.